Skip to main content
main-content

07.07.2016 | SCLC | Online-Artikel

Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF

share
TEILEN

Figure: J-ALEX-study: superiority of alectinib over crizotinib with regard to PFS (ITT population)

Weiterführende Themen